Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Colorectal Neoplasms
• Age: Between 18 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) For the vaccine production stage: A) Patients with histologically confirmed metastatic colorectal cancer who are planned for, or have received no more than 1 cycle of chemotherapy. B) Measurable and unresectable disease according to RECIST v1.1. C) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 2) For study treatment stage: A) Patients with histologically confirmed metastatic colorectal cancer who have been treated with fluoropyrimidine and oxaliplatin in combination with bevacizumab, have not experienced disease progression, and are receiving a fluoropyrimidine and bevacizumab as maintenance chemotherapy. B) ECOG performance status of 0 to 2
  

You may not be eligible for this study if the following are true:

• 1) Patients with microsatellite instability-high disease. 2) Patient has a known tumor mutation burden <1 non-synonymous mutations/megabase. 3) Known DNA Polymerase Epsilon mutations and patients with known BRAFV600E mutations. 4) Known exposure to chimpanzee adenovirus within the prior 6 months, plan to receive a chimpanzee adenovirus-based vaccine in the next 6 months, and/or any history or anaphylaxis in reaction to a vaccination.